JP2024518156A - ブプレノルフィンとナロキソンを含む胃内滞留システム - Google Patents

ブプレノルフィンとナロキソンを含む胃内滞留システム Download PDF

Info

Publication number
JP2024518156A
JP2024518156A JP2023568023A JP2023568023A JP2024518156A JP 2024518156 A JP2024518156 A JP 2024518156A JP 2023568023 A JP2023568023 A JP 2023568023A JP 2023568023 A JP2023568023 A JP 2023568023A JP 2024518156 A JP2024518156 A JP 2024518156A
Authority
JP
Japan
Prior art keywords
segment
arms
naloxone
drug eluting
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518156A5 (enExample
Inventor
ビーズ ヌプラ
カトストラ ジェフリー
アルトルーター デイビッド
Original Assignee
リンドラ セラピューティクス, インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リンドラ セラピューティクス, インコーポレイティド filed Critical リンドラ セラピューティクス, インコーポレイティド
Publication of JP2024518156A publication Critical patent/JP2024518156A/ja
Publication of JP2024518156A5 publication Critical patent/JP2024518156A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023568023A 2021-05-05 2022-05-04 ブプレノルフィンとナロキソンを含む胃内滞留システム Pending JP2024518156A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184734P 2021-05-05 2021-05-05
US63/184,734 2021-05-05
PCT/US2022/072114 WO2022236288A1 (en) 2021-05-05 2022-05-04 Gastric residence systems comprising buprenorphine and naloxone

Publications (2)

Publication Number Publication Date
JP2024518156A true JP2024518156A (ja) 2024-04-25
JP2024518156A5 JP2024518156A5 (enExample) 2025-05-09

Family

ID=83932451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568023A Pending JP2024518156A (ja) 2021-05-05 2022-05-04 ブプレノルフィンとナロキソンを含む胃内滞留システム

Country Status (8)

Country Link
US (1) US20240252483A1 (enExample)
EP (1) EP4333823A4 (enExample)
JP (1) JP2024518156A (enExample)
CN (1) CN117615754A (enExample)
AU (1) AU2022270752A1 (enExample)
CA (1) CA3217611A1 (enExample)
IL (1) IL308210A (enExample)
WO (1) WO2022236288A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020117855A1 (en) 2018-12-03 2020-06-11 Lyndra, Inc. Stomach simulating device
BR112021018496A2 (pt) 2019-03-20 2021-11-30 Lyndra Therapeutics Inc Cápsulas e revestimento de cápsula para formas de dosagem de residência gástrica
AU2020242062B2 (en) 2019-03-20 2025-12-11 Nortiva Bio, Inc. Coatings for gastric residence dosage forms

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501718A (ja) * 2009-08-07 2013-01-17 モノソル アールエックス リミテッド ライアビリティ カンパニー 舌下及び口腔用膜組成物
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
JP2015512924A (ja) * 2012-04-12 2015-04-30 エルテーエス ローマン テラピー−ジステーメ アーゲー オピエート腸溶放出ビーズを含む経口フィルム
JP2017171687A (ja) * 2011-09-19 2017-09-28 オレクソ・アクチエボラゲット オピオイド依存を治療するための新規乱用耐性医薬組成物
JP2019532947A (ja) * 2016-09-30 2019-11-14 リンドラ,インコーポレイティド アダマンタン系薬物の持続的送達のための胃内滞留システム
JP2020523306A (ja) * 2017-06-09 2020-08-06 リンドラ,インコーポレイティド 放出速度調節フィルムを有する胃内滞留システム

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8475832B2 (en) * 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
NZ727659A (en) * 2014-06-11 2021-12-24 Massachusetts Inst Technology Residence structures and related methods
US11576859B2 (en) * 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CN109310639A (zh) * 2016-05-27 2019-02-05 林德拉有限公司 用于胃驻留系统的材料结构

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
JP2013501718A (ja) * 2009-08-07 2013-01-17 モノソル アールエックス リミテッド ライアビリティ カンパニー 舌下及び口腔用膜組成物
JP2017171687A (ja) * 2011-09-19 2017-09-28 オレクソ・アクチエボラゲット オピオイド依存を治療するための新規乱用耐性医薬組成物
JP2015512924A (ja) * 2012-04-12 2015-04-30 エルテーエス ローマン テラピー−ジステーメ アーゲー オピエート腸溶放出ビーズを含む経口フィルム
JP2019532947A (ja) * 2016-09-30 2019-11-14 リンドラ,インコーポレイティド アダマンタン系薬物の持続的送達のための胃内滞留システム
JP2020523306A (ja) * 2017-06-09 2020-08-06 リンドラ,インコーポレイティド 放出速度調節フィルムを有する胃内滞留システム

Also Published As

Publication number Publication date
IL308210A (en) 2024-01-01
CN117615754A (zh) 2024-02-27
US20240252483A1 (en) 2024-08-01
CA3217611A1 (en) 2022-11-10
EP4333823A1 (en) 2024-03-13
AU2022270752A1 (en) 2023-12-07
EP4333823A4 (en) 2025-04-09
WO2022236288A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
JP2024518156A (ja) ブプレノルフィンとナロキソンを含む胃内滞留システム
JP2024503485A (ja) リスペリドンを投与するための胃内滞留システム
JP2025060940A (ja) 胃内滞留システムのための材料構造物
US20250339368A1 (en) Dosage forms for gastric retention
PT2526932T (pt) Composição farmacêutica
JP2024517829A (ja) メタドンを含む胃内滞留システム
JP2010502642A (ja) バルサルタンのための持続放出性胃滞留型経口薬物送達システム
JP2025531626A (ja) 胃内滞留システムを用いたリスペリドンの投与レジメン
CA3118056A1 (en) Systems for enteric delivery of therapeutic agents
CN115003336A (zh) 用于胃驻留系统的聚合物连接体
CN121908982A (zh) 胃滞留系统的制备方法
CN117083059A (zh) 用于利培酮施用的胃滞留系统
TWI837082B (zh) 用於胃滯留系統之材料架構
CN118871091A (zh) 用于胃滞留的剂型
WO2025199123A1 (en) Flexible line configurations for gastric residence systems
TW202500122A (zh) 用於胃滯留系統之材料架構

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260331

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260422